EA201591638A1 - Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита - Google Patents

Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита

Info

Publication number
EA201591638A1
EA201591638A1 EA201591638A EA201591638A EA201591638A1 EA 201591638 A1 EA201591638 A1 EA 201591638A1 EA 201591638 A EA201591638 A EA 201591638A EA 201591638 A EA201591638 A EA 201591638A EA 201591638 A1 EA201591638 A1 EA 201591638A1
Authority
EA
Eurasian Patent Office
Prior art keywords
osteoarthritis
acid
joint introduction
souldronic
steroids
Prior art date
Application number
EA201591638A
Other languages
English (en)
Other versions
EA032067B1 (ru
Inventor
Кетан Десай
Original Assignee
Леволта Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Леволта Фармасьютикалс, Инк. filed Critical Леволта Фармасьютикалс, Инк.
Publication of EA201591638A1 publication Critical patent/EA201591638A1/ru
Publication of EA032067B1 publication Critical patent/EA032067B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

Раскрывается комбинированная терапия для лечения остеоартрита. Комбинированная терапия предусматривает совместное введение стероида и золедроновой кислоты. Совместное введение стероида снижает продуцирование цитокинов и тем самым снижает провоспалительные эффекты золедроновой кислоты. Совместное введение золедроновой кислоты со стероидом лечит остеоартрит и помогает предупреждать наступление остеоартрита у пациентов с риском остеоартрита.
EA201591638A 2013-03-08 2014-03-07 Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита EA032067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
EA201591638A1 true EA201591638A1 (ru) 2016-02-29
EA032067B1 EA032067B1 (ru) 2019-04-30

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591638A EA032067B1 (ru) 2013-03-08 2014-03-07 Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита

Country Status (12)

Country Link
US (1) US9012432B2 (ru)
EP (1) EP2964209B1 (ru)
JP (2) JP6839491B2 (ru)
KR (1) KR102253394B1 (ru)
CN (1) CN105324113B (ru)
AU (1) AU2014225373B2 (ru)
BR (1) BR112015021503B1 (ru)
CA (1) CA2941346C (ru)
EA (1) EA032067B1 (ru)
ES (1) ES2904365T3 (ru)
MX (1) MX2015011671A (ru)
WO (1) WO2014138712A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
WO2017155233A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
WO2002100408A2 (en) * 2001-06-08 2002-12-19 Ortho-Mcneil Pharmaceutical, Inc. Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
EP1667691A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
AU2005254155A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
MY149863A (en) * 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20100158905A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
EP2427160A4 (en) * 2009-05-04 2012-12-19 Zars Pharma Inc METHOD FOR TREATING PAIN RELATED TO NEUROMAS, NERVE CLAIMS AND OTHER SUFFERING PAINS
US8946199B2 (en) 2010-04-26 2015-02-03 Ketan Desai Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion

Also Published As

Publication number Publication date
BR112015021503B1 (pt) 2022-09-06
KR20150125001A (ko) 2015-11-06
MX2015011671A (es) 2016-05-12
EP2964209B1 (en) 2021-10-27
JP2016510765A (ja) 2016-04-11
US9012432B2 (en) 2015-04-21
WO2014138712A1 (en) 2014-09-12
JP6839491B2 (ja) 2021-03-17
US20140256681A1 (en) 2014-09-11
KR102253394B1 (ko) 2021-05-20
EA032067B1 (ru) 2019-04-30
CA2941346C (en) 2020-03-10
EP2964209A1 (en) 2016-01-13
CN105324113A (zh) 2016-02-10
AU2014225373B2 (en) 2018-07-05
ES2904365T3 (es) 2022-04-04
EP2964209A4 (en) 2016-08-03
CA2941346A1 (en) 2014-09-12
BR112015021503A2 (pt) 2018-05-15
AU2014225373A1 (en) 2015-10-22
JP2019104762A (ja) 2019-06-27
CN105324113B (zh) 2018-07-03

Similar Documents

Publication Publication Date Title
EA201591638A1 (ru) Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
EA201790737A1 (ru) Комбинированная терапия
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
EA201991484A1 (ru) Лекарственные формы энзалутамида
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
IN2015DN00450A (ru)
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
IL275913A (en) Methods and combined treatment for cancer treatment
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
GB201518063D0 (en) Chrono-parenteral administration of high-dose melatonin to treat severe disrupted circadian rhythm in critically ill patients
RU2014150855A (ru) Способ лечения сексуальной дисфункции у пациентов с хроническим простатитом
UA93178U (ru) Способ лечения хронического тонзиллита у детей

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM